MA39441A1 - Composition d'insuline a action rapide - Google Patents

Composition d'insuline a action rapide

Info

Publication number
MA39441A1
MA39441A1 MA39441A MA39441A MA39441A1 MA 39441 A1 MA39441 A1 MA 39441A1 MA 39441 A MA39441 A MA 39441A MA 39441 A MA39441 A MA 39441A MA 39441 A1 MA39441 A1 MA 39441A1
Authority
MA
Morocco
Prior art keywords
fast
acting insulin
insulin composition
insulin analog
composition
Prior art date
Application number
MA39441A
Other languages
English (en)
Inventor
Micheal Edward Christe
Thomas Andrew Hardy
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53189204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39441(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA39441A1 publication Critical patent/MA39441A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur une composition d'insuline humaine ou d'analogue d'insuline qui comprend du tréprostinil et qui possède une action pharmacocinétique plus rapide par rapport aux formulations commerciales de produits analogues d'insuline existants.
MA39441A 2014-05-08 2015-05-04 Composition d'insuline a action rapide MA39441A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461990402P 2014-05-08 2014-05-08
PCT/US2015/029010 WO2015171484A1 (fr) 2014-05-08 2015-05-04 Compositions d'insuline à action rapide

Publications (1)

Publication Number Publication Date
MA39441A1 true MA39441A1 (fr) 2017-06-30

Family

ID=53189204

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39441A MA39441A1 (fr) 2014-05-08 2015-05-04 Composition d'insuline a action rapide

Country Status (36)

Country Link
US (2) US9439952B2 (fr)
EP (3) EP3943155A1 (fr)
JP (1) JP6050902B2 (fr)
KR (1) KR101858890B1 (fr)
CN (1) CN106456717B (fr)
AP (1) AP2016009525A0 (fr)
AR (1) AR100155A1 (fr)
AU (1) AU2015256355B2 (fr)
BR (1) BR112016024357B1 (fr)
CA (1) CA2945188C (fr)
CL (1) CL2016002772A1 (fr)
CY (2) CY1121669T1 (fr)
DK (2) DK3140008T3 (fr)
EA (1) EA031134B1 (fr)
ES (2) ES2733639T3 (fr)
HR (2) HRP20190777T1 (fr)
HU (2) HUE044370T2 (fr)
IL (1) IL248350B (fr)
JO (1) JO3624B1 (fr)
LT (2) LT3140008T (fr)
MA (1) MA39441A1 (fr)
ME (1) ME03384B (fr)
MX (1) MX367521B (fr)
NZ (1) NZ724919A (fr)
PE (1) PE20161408A1 (fr)
PH (1) PH12016502195B1 (fr)
PL (2) PL3536380T3 (fr)
PT (2) PT3140008T (fr)
RS (2) RS58726B1 (fr)
SG (1) SG11201608424WA (fr)
SI (2) SI3140008T1 (fr)
TN (1) TN2016000443A1 (fr)
TR (1) TR201906843T4 (fr)
TW (1) TWI685348B (fr)
UA (1) UA124919C2 (fr)
WO (1) WO2015171484A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
KR20150082640A (ko) 2012-11-13 2015-07-15 아도시아 치환된 음이온성 화합물을 포함하는 속효성 인슐린 제형
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9371264B2 (en) 2013-01-11 2016-06-21 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
ES2972423T3 (es) * 2015-07-28 2024-06-12 Lilly Co Eli Preparado farmacéutico para mejorar la absorción y la acción hipoglucemiante postprandial de la insulina
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
JP2019504684A (ja) * 2016-01-29 2019-02-21 マンカインド コーポレイション 乾燥粉末吸入器
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
EP3515430A1 (fr) 2016-09-26 2019-07-31 United Therapeutics Corporation Promédicaments de tréprostinil
AU2017334290B2 (en) 2016-09-29 2023-04-20 Arecor Limited Novel formulations
MA49116A (fr) 2016-12-16 2020-03-25 Novo Nordisk As Compositions pharmaceutiques contenant de l'insuline
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707187D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
WO2018222787A1 (fr) * 2017-06-01 2018-12-06 Eli Lilly And Company Compositions d'insuline à action rapide
WO2019193349A1 (fr) 2018-04-04 2019-10-10 Arecor Limited Système de pompe à perfusion médicale pour l'administration d'un composé d'insuline
IL277721B2 (en) 2018-04-04 2024-03-01 Arecor Ltd Medical infusion pump system for the delivery of an insulin compound
US20210113763A1 (en) 2018-04-04 2021-04-22 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
US12102610B2 (en) 2018-09-18 2024-10-01 Eli Lilly And Company Treprostinil salt
US10799564B1 (en) 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same
CN114096269B (zh) 2019-07-12 2024-06-11 诺和诺德股份有限公司 高浓度胰岛素制剂
JP2022546314A (ja) 2019-08-23 2022-11-04 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグ
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations
US11826327B2 (en) 2020-04-17 2023-11-28 United Therapeutics Corporation Treatment for interstitial lung disease
KR20250057075A (ko) 2020-06-09 2025-04-28 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐의 푸마릴 디케토피페리딘 프로드러그
TW202214292A (zh) * 2020-06-30 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 速效胰島素組成物及其醫藥用途
JP7826317B2 (ja) 2020-12-14 2026-03-09 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグで疾患を治療する方法
EP4301372A1 (fr) 2021-03-03 2024-01-10 United Therapeutics Corporation Composition de poudre sèche de treprostinil et son promédicament et comprenant en outre de l'(e)-3,6-bis[4-(n-carbonyl-2-propényl)amidobutyl]-2,5-dicétopipérazine (fdkp)
KR20250002687A (ko) * 2022-04-29 2025-01-07 자오커 파마슈티컬 (광저우) 컴퍼니., 리미티드 트레프로스티닐 소프트 미스트 흡입제

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2740953A1 (de) 1977-09-12 1979-03-22 Thera Ges Fuer Patente Verwendung von prostaglandinen zur senkung des blutzuckerspiegels
JPH10251146A (ja) * 1997-03-11 1998-09-22 Toray Ind Inc 糖尿病性神経障害の治療方法
WO2003020201A2 (fr) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-melanges de polypeptide glp-1 et d'insuline basale
ATE496064T1 (de) * 2002-05-07 2011-02-15 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
CN101287457B (zh) * 2004-04-12 2011-11-16 联合治疗公司 Treprostinil用于治疗神经性糖尿病的足部溃疡的用途
EP2190433A2 (fr) * 2007-08-22 2010-06-02 Gilead Colorado, Inc. Thérapie pour complications du diabète
US9387033B2 (en) 2008-08-28 2016-07-12 Roche Diabetes Care, Inc. Device and method for enhanced subcutaneous insulin absorption
EP2330893A4 (fr) * 2008-09-25 2013-01-09 Aradigm Corp Administration pulmonaire profonde de tréprostinil
KR101775000B1 (ko) 2009-06-26 2017-09-04 노보 노르디스크 에이/에스 인슐린, 니코틴아미드 및 아미노산을 포함하는 제제
BR112012011237A2 (pt) * 2009-11-13 2019-09-24 Univ Tokyo agente terapêutico e profilático para diabetes
CN103328006A (zh) 2010-12-14 2013-09-25 诺沃—诺迪斯克有限公司 包含胰岛素、烟酰胺和氨基酸的制剂
JP6092867B2 (ja) * 2011-08-12 2017-03-08 アセンディス ファーマ エー／エス 担体連結しているトレプロスチニルプロドラッグ
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US20150065423A1 (en) 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
WO2015120457A1 (fr) 2014-02-10 2015-08-13 Biodel Inc. Formulations d'insuline à action ultrarapide stabilisées

Also Published As

Publication number Publication date
PT3536380T (pt) 2021-09-02
EA031134B1 (ru) 2018-11-30
US9439952B2 (en) 2016-09-13
IL248350B (en) 2020-03-31
EA201691911A1 (ru) 2017-02-28
UA124919C2 (uk) 2021-12-15
AU2015256355B2 (en) 2017-09-14
DK3536380T3 (da) 2021-08-02
KR20160133567A (ko) 2016-11-22
PH12016502195A1 (en) 2017-02-06
CA2945188C (fr) 2018-12-11
ME03384B (fr) 2020-01-20
HUE055742T2 (hu) 2021-12-28
HRP20211415T1 (hr) 2021-12-10
TR201906843T4 (tr) 2019-05-21
PE20161408A1 (es) 2016-12-28
EP3536380B8 (fr) 2021-09-22
PT3140008T (pt) 2019-06-25
TN2016000443A1 (en) 2018-04-04
CL2016002772A1 (es) 2017-06-09
JO3624B1 (ar) 2020-08-27
SI3536380T1 (sl) 2021-09-30
RS62291B1 (sr) 2021-09-30
PH12016502195B1 (en) 2017-02-06
MX2016014643A (es) 2017-03-06
EP3140008A1 (fr) 2017-03-15
LT3536380T (lt) 2021-08-10
CY1121669T1 (el) 2020-07-31
BR112016024357A2 (pt) 2017-10-10
US10172922B2 (en) 2019-01-08
SG11201608424WA (en) 2016-11-29
EP3536380A1 (fr) 2019-09-11
AU2015256355A1 (en) 2016-10-27
AP2016009525A0 (en) 2016-10-31
AR100155A1 (es) 2016-09-14
CA2945188A1 (fr) 2015-11-12
JP6050902B2 (ja) 2016-12-21
EP3943155A1 (fr) 2022-01-26
DK3140008T3 (da) 2019-06-24
PL3140008T3 (pl) 2019-09-30
MX367521B (es) 2019-08-26
KR101858890B1 (ko) 2018-05-16
PL3536380T3 (pl) 2021-12-27
CN106456717B (zh) 2020-01-17
ES2891983T3 (es) 2022-02-01
HRP20190777T1 (hr) 2019-08-23
JP2016523807A (ja) 2016-08-12
HUE044370T2 (hu) 2019-10-28
SI3140008T1 (sl) 2019-06-28
ES2733639T3 (es) 2019-12-02
CN106456717A (zh) 2017-02-22
US20160367640A1 (en) 2016-12-22
EP3140008B1 (fr) 2019-04-17
US20160129087A1 (en) 2016-05-12
EP3536380B1 (fr) 2021-07-07
IL248350A0 (en) 2016-11-30
TWI685348B (zh) 2020-02-21
TW201625291A (zh) 2016-07-16
BR112016024357B1 (pt) 2022-08-23
WO2015171484A1 (fr) 2015-11-12
NZ724919A (en) 2018-01-26
LT3140008T (lt) 2019-05-27
CY1124454T1 (el) 2022-07-22
RS58726B1 (sr) 2019-06-28

Similar Documents

Publication Publication Date Title
MA39441A1 (fr) Composition d'insuline a action rapide
MX379267B (es) Composiciones de insulina de rapida accion.
MA41188B1 (fr) Compositions d'insuline à action rapide
SG10201809427SA (en) Insulin receptor partial agonists
ZA201705114B (en) Cysteine protease
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
MX2017010390A (es) Proteasa de cisteina.
MX2016008978A (es) Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
PH12015502331A1 (en) Formulations of oxabicycloheptanes and oxabicycloheptenes
NZ728662A (en) A process for purification of rhu-gcsf
EP3844279A4 (fr) Produits et compositions
PH12019502677A1 (en) Rapid-acting insulin compositions
BR112017012524A2 (pt) composição contendo éster parcial de carboidrato
IL262729A (en) Compositions and methods of providing thyroid hormone or analogs thereof
BR112017024395A2 (pt) aplicador por spray de maior alcance